Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Twenty patients with advanced progressing Parkinson's disease have been treated with the 8-alpha-ergoline CU 32-085 in combination therapy for 3 months. With a mean daily dose of 12.65 mg, CU 32-085 together with levodopa plus a decarboxylase inhibitor produced a significant reduction in akinesia, rigor and tremor. Adverse reactions were rare and mild; in one case the drug was discontinued because of dyskinetic movements. Many of the pre-existing side effects were reduced or eliminated, particularly the involuntary movements and the levodopa response swings. The compound was considered useful in the treatment of advanced, progressing Parkinson's disease.
D000328:Adult; D000368:Aged; D000547:Amantadine / Q000008:administration & dosage; D000978:Antiparkinson Agents; D001971:Bromocriptine / Q000008:administration & dosage; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D004873:Ergolines; D010276:Parasympatholytics; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine; D002262:Carboxy-Lyases; C031649:mesulergine